US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 02:24:09 Source:styleViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Ship that caused Baltimore bridge collapse has been refloated
Next:Dodgers acquire pitcher Yohan Ramírez from Mets for cash
You may also like
- Cannes 2024: Studio Ghibli takes a bow with an honorary Palme d'Or
- Rishi Sunak faces backlash on prisons as government triggers emergency overcrowding plan
- Tragic toddler, three, drowned in the bath after switching the taps on at home, inquest hears
- Deliveroo transports food to customers in west London on penny farthing bicycle from 1880s
- What a blast to work at NASA. Space agency is sky
- Stock market today: World shares are mixed after Wall St hits fresh records on hopes for rate cuts
- Beaming Charles hobnobs with Tess Daly, Sir Lenny Henry and supermodel Rosie Huntington
- Cannes Film Festival: Anya
- Ben Whishaw lights up the Croisette as he joins his co